Biogen Inc. (BIIB): Total Assets
$29.44B
As of 2025-12-31
$29.48B
As of 2026-03-31
+6.2%
3-year compound annual growth
+3.6%
5-year compound annual growth
+4.2%
10-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $29.44B | +5.0% | 2026-02-06, Balance as of period end |
| 2024-12-31 | $28.05B | +4.5% | 2026-02-06, Balance as of period end |
| 2023-12-31 | $26.84B | +9.3% | 2025-02-12, Balance as of period end |
| 2022-12-31 | $24.55B | +2.8% | 2024-02-14, Balance as of period end |
| 2021-12-31 | $23.88B | -3.0% | 2023-02-15, Balance as of period end |
| 2020-12-31 | $24.62B | -9.6% | 2022-02-03, Balance as of period end |
| 2019-12-31 | $27.23B | +7.7% | 2021-02-03, Balance as of period end |
| 2018-12-31 | $25.29B | +6.9% | 2020-02-06, Balance as of period end |
| 2017-12-31 | $23.65B | +3.4% | 2019-02-06, Balance as of period end |
| 2016-12-31 | $22.88B | +17.3% | 2018-02-01, Balance as of period end |
| 2015-12-31 | $19.50B | +36.3% | 2017-02-02, Balance as of period end |
| 2014-12-31 | $14.31B | +20.7% | 2016-02-03, Balance as of period end |
| 2013-12-31 | $11.86B | +17.1% | 2015-02-04, Balance as of period end |
| 2012-12-31 | $10.13B | +11.9% | 2014-02-06, Balance as of period end |
| 2011-12-31 | $9.05B | +11.8% | 2013-02-05, Balance as of period end |
| 2010-12-31 | $8.09B | -5.4% | 2012-02-03, Balance as of period end |
| 2009-12-31 | $8.55B | +0.9% | 2011-02-04, Balance as of period end |
| 2008-12-31 | $8.48B | n/a | 2010-02-09, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Biogen Inc. (BIIB) | 2025-12-31 | $29.44B | +5.0% |
| Gilead Sciences, Inc. (GILD) | 2025-12-31 | $59.02B | 0.0% |
| Neurocrine Biosciences Inc (NBIX) | 2025-12-31 | $4.63B | +24.5% |
| Amgen Inc (AMGN) | 2025-12-31 | $90.59B | -1.4% |
| Exelixis, Inc. (EXEL) | 2026-01-02 | $2.84B | -3.5% |
| Qiagen N.V. (QGEN) | 2025-12-31 | $6.28B | +10.4% |
| Moderna, Inc. (MRNA) | 2025-12-31 | $12.34B | -12.8% |
| Halozyme Therapeutics, Inc. (HALO) | 2025-12-31 | $2.53B | +22.4% |
| Bio-Techne Corp (TECH) | 2026-06-30 | $2.59B | +1.1% |
Compare BIIB, GILD, NBIX, AMGN side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗